Check your dad jeans — and genes — in J&J's new BRCA-focused campaign

26 Jan 2024

Drug Approval

Many people are familiar with BRCA, or breast cancer gene 1 and 2, mutations in breast cancer, but they can also play a role in prostate cancer. J&J is tackling the subject in new communications and adding light-hearted humor with its “Dad Genes” website. On BRCAInMen.com, men, boys and a few women wear high-waisted and belted baggy denim to make the visual jeans/genes homonym pun. While the new work is unbranded, J&J’s oral prostate cancer combination drug Akeega (niraparib and abiraterone acetate) was approved in August to treat people with BRCA-positive metastatic castration-resistant prostate cancer.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Johnson & Johnson

Indications

Breast CancerProstatic CancerBRCA Mutation Castration-Resistant Prostate Cancer

Targets

Drugs

Niraparib Tosylate/Abiraterone AcetateNiraparib TosylateAbiraterone acetate

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.